Omalizumab
| Use attributes for filter ! | |
| CAS ID | 242138-07-4 |
|---|---|
| Formula | C6450H9916N1714O2023S38 |
| Molar mass | 145058. 2 g/mol g·mol−1 |
| Trade name | Xolair |
| Target | IgE |
| Fc region | |
| Elimination half-life | 26 days |
| Music groups | Mepolizumab |
| Dupilumab | |
| Montelukast | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2951282 |
About Omalizumab
Omalizumab, sold under the trade name Xolair, is a medication originally designed to reduce sensitivity to allergens. It has been used to try to control severe allergic asthma, which does not respond to high doses of corticosteroids and less widely for chronic spontaneous urticaria.